"Improved in vitro Growth Inhibitory Effect of N-(phosphonacetyl)-L-Aspartic Acid in Immunoliposomes."

According to the authors' abstract of an article published in Journal of Controlled Release, "The use of liposome-encapsulated N-(phosphonacetyl)-L-aspartic acid (PALA) for the possible treatment of human ovarian cancer has been investigated in vitro. Protein A or tumor-specific antibodies were conjugated to liposomes via the reaction of a maleimide derivatized phospholipid (MPB-PE) with a thiol introduced into the protein by a heterobifunctional cross-linking agent, N-succimidyl 3-(2-pyridyldithio) propionate (SPDP). Antibody-conjugated PALA-containing liposomes were separated from free antibodies by ultracentrifugation in discontinuous metrizamide gradients. PALA in Protein...

Want to see the full article?

• Purchase this article for only $3.00